Myndtec, Inc.

Myndtec, Inc. specializes in transcutaneous neuromuscular electrical stimulation (NMES) systems for physical therapy. Their portfolio includes systems like the MyndMove (used for muscle activation and rehabilitation) and the MyndStep (likely for gait training or lower-limb recovery). They also produce neuromuscular transmission electrodes and sensor leads, which are components used alongside these systems to deliver targeted electrical stimulation.

Myndtec, Inc. is headquartered in the United States. Their neuromuscular stimulation devices are authorised for commercial distribution in the U.S. under FDA regulations, which govern their classification and listing requirements.

Myndtec’s neuromuscular stimulation devices fall under Class II classification by the FDA. This classification means they require premarket notification (510(k)) or unique device identification (UDI) listing before being marketed. Class II devices are considered to have moderate risk and require special controls beyond general controls to ensure safety and effectiveness, which is why they must comply with these regulatory pathways.

Myndtec’s devices are listed in the FDA’s 510(k) premarket notification database and the FDA’s Unique Device Identification (UDI) system. These registries track authorised medical devices in the U.S. to ensure compliance with FDA requirements. No additional regulatory registries outside the FDA framework are referenced for their products.

Because Myndtec’s neuromuscular stimulation devices are Class II under FDA regulations, they are subject to special controls that require either a 510(k) premarket notification (to demonstrate substantial equivalence to a predicate device) or UDI listing (to ensure traceability and transparency in the supply chain). These requirements help ensure the devices meet safety and performance standards before entering the market.